|
![]() |
|||
|
||||
OverviewThe Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system—including psychiatric drugs—are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future. Table of Contents Front Matter Introduction 1 Perspectives from the FDA, Academia, and Patients 2 Data Collection and Optimization 3 Data Analysis 4 Partnerships, Opportunities, Collaboration Appendix A: References Appendix B: Workshop Agenda Appendix C: Workshop Attendees Appendix D: Biographical Sketches of Invited Speakers Full Product DetailsAuthor: Institute of Medicine , Board on Health Sciences Policy , Forum on Neuroscience and Nervous System Disorders , Bruce AltevogtPublisher: National Academies Press Imprint: National Academies Press ISBN: 9780309148832ISBN 10: 0309148839 Pages: 88 Publication Date: 22 January 2011 Audience: Professional and scholarly , Professional & Vocational Format: Paperback Publisher's Status: Active Availability: In Print ![]() This item will be ordered in for you from one of our suppliers. Upon receipt, we will promptly dispatch it out to you. For in store availability, please contact us. Table of Contents1 Front Matter; 2 Introduction; 3 1 Perspectives from the FDA, Academia, and Patients; 4 2 Data Collection and Optimization; 5 3 Data Analysis; 6 4 Partnerships, Opportunities, Collaboration; 7 Appendix A: References; 8 Appendix B: Workshop Agenda; 9 Appendix C: Workshop Attendees; 10 Appendix D: Biographical Sketches of Invited SpeakersReviewsAuthor InformationTab Content 6Author Website:Countries AvailableAll regions |